News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027
Pentixapharm Holding AG raises 2026 earnings guidance, expects first-patient enrollment in PANDA Phase 3 study by Q1 2027, with reduced net loss and extended cash runway